# ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

Source: https://onco.cc/trials/nct07381764/  
OnCo record `nct07381764` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cetuximab, bevacizumab (glioblastoma use), fOLFIRI (5-FU, leucovorin, irinotecan) and trifluridine/tipiracil in colorectal cancer, run by Gruppo Oncologico Italia Meridionale, now recruiting.

## Summary

ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer" is a phase 2, randomised interventional study registered as NCT07381764 by Gruppo Oncologico Italia Meridionale, with a registry enrolment figure of 150 participants, started 2026-03-20 and due to reach its primary completion in 2031-03-30. Interventions recorded: Erbitux (Cetuximab); Bevacizumab; Irinotecan; Trifluridine/tipiracil. Conditions listed: Metastatic Colorectal Cancer (CRC). Primary outcome: Objective Response Rate (ORR). Colorectal eligibility wording from the registry: "Diagnosis of histologically or cytologically confirmed colorectal cancer". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: ROMANCE - GOIM
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07381764
- Phase: 2
- Setting: ROMANCE GOIM Study: A Phase II, Open Label, Multicenter Trial Investigating Irinotecan Plus Cetuximab Rechallenge Compared With Trifluridine/Tipiracil Plus Bevacizumab as Third Line Treatment in Circulating Tumor DNA Molecularly Selected Metastatic Colorectal Cancer
- Sponsor: Gruppo Oncologico Italia Meridionale
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07381764: https://clinicaltrials.gov/study/NCT07381764

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Trifluridine/tipiracil](https://onco.cc/drugs/trifluridine-tipiracil/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07381764.json